A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease

Hepatology

Volumn 42, Issue 3, 2005, Pages 665-674

  Younossi, Zobair M ^a,b   Baranova, Ancha ^b   Ziegler, Katharine ^b   Del Giacco, Luca ^b   Schlauch, Karen ^a,b   Born, Timothy L ^b   Elariny, Hazem ^a   Gorreta, Francesco ^b   VanMeter, Amy ^b   Younoszai, Abraham ^a   Ong, Janus P ^a,b   Goodman, Zachary ^c   Chandhoke, Vikas ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLUCOSE; GLUTATHIONE TRANSFERASE; HYALURONIC ACID; INSULIN; KERATIN; LEPTIN; PLASMA PROTEIN; RNA; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEATOSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY;

ADULT; BODY MASS INDEX; BODY SIZE; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; GENOMICS; HUMANS; MALE; OBESITY; OBESITY, MORBID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTEINS; PROTEOMICS; UNITED STATES;

EID: 24144503408     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20838     Document Type: Article

References (50)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
2. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
3. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences wich a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
4. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. HEPATOLOGY 2002;35:746-752.
5. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121:710-723.
6. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
7. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. HEPATOLOGY 1995;22:1714-1719.
8. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. HEPATOLOGY 1999;29:664-669.
9. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001;7:797-801.
10. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
11. Day CP, James OFW. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845.
12. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
13. Belfiore F, Iannello S. Insulin resistance in obesity: metabolic mechanisms and measurement methods. Mol Genet Metab 1998;65:121-128.
14. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
15. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-1476.
16. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. HEPATOLOGY 2000;32:3-10.
17. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 1999;282:1659-1664.
18. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114:311-318.
19. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, et al. Hepatic iron and nonalcoholic fatty liver disease. HEPATOLOGY 1999;30:847-850.
20. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001;21:266-271.
21. Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. HEPATOLOGY 1999;29:1131-1138.
22. Guttmacher AE, Collins FS. Genomic medicine-a primer. N Engl J Med 2002;347:1512-1520.
23. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ. Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 2005;230: 95-106.
24. Issaq HJ, Conrads TP, Prieto DA, Tirumalai R, Veenstra TD. SELDITOF MS for diagnostic proteomics. Anal Chem 2003;75:148A-155A.
25. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587-592.
26. Melle C, Kaufmann R, Hommann M, Bleul A, Driesch D, Ernst G, et al. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int J Oncol 2004;24:885-891.
27. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. HEPATOLOGY 2004;41:40-47.
28. Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001;120:955-966.
29. Collins FS, Guttmacher AE. Genetics moves into the medical mainstream. JAMA 2001;286:2322-2324.
30. Epstein CB, Hale W, Butow R. Numerical methods for handling uncertainty in microarray data: an example analyzing perturbed mitochondrial function in yeast. Methods Cell Biol 2001;65:439-452.
31. Younossi Z, Gorreta F, Ong J, Schlauch K, Del Giacco L, Elariny H, et al. Hepatic gene expression in patients with obesity related non-alcoholic steatohepatitis. Liver Int 2005;25:760-771.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B. 1995;57:289-300.
33. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001;21:81-88.
34. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998;11:560-565.
35. James OF, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998;29:495-501.
36. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. HEPATOLOGY 1990;11:74-80.
37. Augulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. HEPATOLOGY 1999; 30:1356-1362.
38. Grant G, Chandhoke V, Younossi Z. Specific disorders associated with non-alcoholic fatty liver disease (NAFLD). In: Farrell G, George J, Hall P, McCullough A, eds. Fatty Liver Diseases: Non-Alcoholic Steatohepatitis and Related Disorders. 1st ed. Malden, MA: Blackwell Publishers, 2004: 249-262.
39. Lui HM, Chen J, Wang L, Naumovski L. ARMER, apoptotic regulator in the membrane of the endoplasmic reticulum, a novel inhibitor of apoptosis. Mol Cancer Res 2003;1:508-518.
40. Steiling H, Muhlbauer M, Bataille F, Scholmerich J, Werner S, Hellerbtand C. Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. Am J Pathol 2004;165:1233-1241.
41. Toivola DM, Zhou Q, English LS, Omary MB. Type II keratins are phosphorylated on a unique motif during stress and mitosis in tissues and cultured cells. Mol Biol Cell 2002;13:1857-1870.
42. Omary MB, Ku NO, Toivola DM. Keratins: guardians of the liver. HEPATOLOGY 2002;35:251-257.
43. Martin H, Richert L, Berthelot A. Magnesium deficiency induces apoptosis in primary cultures of rat hepatocytes. J Nutr 2003;133:2505-2511.
44. Chan K, Lucas D, Hise D, Schaefer C, Xiao Z, Janini G, et al. Analysis of the human serum proteome. Clinical Proteomics 2004;101-226.
45. Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005;51:328-335.
46. Xu XQ, Leow CK, Lu X, Zhang X, Liu JS, Wong WH, et al. Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics. Proteomics 2004;4:3235-3245.
47. Farrell DH. Pathophysiologic roles of the fibrinogen gamma chain. Curr Opin Hematol 2004;11:151-155.
48. Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 2004;559:107-110.
49. Yu C, Wang F, Jin C, Huang X, Miller DL, Basilico C, et al. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol 2003;163:1653-1662.
50. Sahni A, Francis CW. Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J Thromb Haemost 2003;1:1271-1277.